Publication details
Zahájit, či nezahájit perorální antikoagulaci u pacientů s fibrilací síní po krvácení do mozku? Dostupné důkazy a probíhající studie
| Title in English | To initiate or not to initiate oral anticoagulation in patients with atrial fibrillation after cerebral hemorrhage? Available evidence and ongoing studies |
|---|---|
| Authors | |
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | CMP Journal |
| MU Faculty or unit | |
| Citation | |
| web | https://www.prolekare.cz/casopisy/cmp-journal/2024-1-19/download?hl=cs |
| Keywords | Oral Anticoagulant Therapy; stroke; STROZECH |
| Description | Oral anticoagulant treatment plays an irreplaceable role in the secondary prevention of cardioembolic events ischemic stroke (iCMP). If there is no contraindication, they are primarily indicated substances from the group of direct oral anticoagulants (DOACs) – dabigatran, apixaban, edoxaban and rivaroxaban [1]. They have these drugs favorable pharmacological profile (compared to warfarin) and represent a clear benefit for patients in in the sense of minimizing the risk of recurrence of cardiovascular complications. In patients with iCMP and captured atrial fibrillation (FiS), it was shown that early initiation of anticoagulation with DOACs is effective (start timing according to brain extent heart attack) and at the same time safe (low risk of symptomatic intracerebral hemorrhage /ICH/ as a result |